Dilafor

Focus: Dilafor is a Swedish biotechnology company focused on developing Low Anticoagulant Heparin (LAH) derivatives for cardiovascular and obstetric applications. The company operates as a specialized biotech with a narrow, targeted pipeline.

Cardiovascular

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Dilafor

AI assessmentNot Hiring

No open roles listed right now. Follow Dilafor to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

3 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

DF 01

Labor, Obstetric

PHASE_2

Clinical Trials (1)

NCT03001193Effect of Tafoxiparin to Treat Primary Slow Progress of Labor Including Prolonged Latent Phase and Labor Arrest

Phase 2

Help build intelligence for Dilafor

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused pipeline in unmet obstetric needs—DF01 addresses labor abnormalities with minimal anticoagulant side effects, a differentiated mechanism
Early-stage biotech environment offers hands-on involvement in clinical development and regulatory strategy across multiple Phase 2 indications
Swedish location provides access to strong Nordic healthcare infrastructure and regulatory relationships with EMA

Watch Out For

No active hiring (0 open roles)—limited near-term employment opportunities or company growth signals
Pre-revenue status with unknown funding and financials introduces significant execution and cash runway risk
Narrow therapeutic focus (obstetrics only) limits internal mobility and career optionality if direction shifts

Generated by Claude from Dilafor's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

DF01

Pregnancy

PHASE_2

Clinical Trials (1)

NCT00710242Study to Assess Safety and Efficacy of DF01 in Reducing Prolonged Labor

Phase 2

DF01

Labor Onset and Length Abnormalities

PHASE_2

Clinical Trials (1)

NCT04000438Effect of Tafoxiparin on Cervical Ripening and Induction of Labor in Term Pregnant Women With an Unripe Cervix

Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 3 clinical trials

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo